24-Dec-2025
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire (Tue, 16-Dec 4:01 PM ET)
Business Wire (Fri, 5-Dec 9:00 AM ET)
Globe Newswire (Fri, 5-Dec 9:00 AM ET)
Business Wire (Mon, 1-Dec 7:30 AM ET)
Globe Newswire (Mon, 1-Dec 7:30 AM ET)
Business Wire (Mon, 17-Nov 7:30 AM ET)
Globe Newswire (Mon, 17-Nov 7:30 AM ET)
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Business Wire (Wed, 5-Nov 4:01 PM ET)
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Business Wire (Tue, 4-Nov 4:01 PM ET)
Business Wire (Thu, 30-Oct 4:30 PM ET)
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Stoke Therapeutics trades on the NASDAQ stock market under the symbol STOK.
As of December 24, 2025, STOK stock price climbed to $32.17 with 234,979 million shares trading.
STOK has a beta of 1.94, meaning it tends to be more sensitive to market movements. STOK has a correlation of 0.18 to the broad based SPY ETF.
STOK has a market cap of $1.84 billion. This is considered a Small Cap stock.
Last quarter Stoke Therapeutics reported $11 million in Revenue and -$.65 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.07.
In the last 3 years, STOK traded as high as $38.69 and as low as $3.35.
The top ETF exchange traded funds that STOK belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
STOK has outperformed the market in the last year with a price return of +177.1% while the SPY ETF gained +17.3%. STOK has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +42.2% and +5.6%, respectively, while the SPY returned +4.4% and +1.4%, respectively.
STOK support price is $30.41 and resistance is $33.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STOK shares will trade within this expected range on the day.
